Lipegfilgrastim

Summary

Lipegfilgrastim (CHEMBL4594230) is an approved protein (ATC L03AA14); indicated across 4 conditions including neoplasm and neutropenia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AA14
• Indications: 4 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594230
Name	Lipegfilgrastim
Type	Protein
Max phase	4
ATC	L03AA14

Also known as: Lipegfilgrastim, Lonquex, XM-22, XM22, LIPEGFILGRASTIM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
neutropenia	4	MONDO:0001475	MONDO:0001475

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
lymphoma	3	MONDO:0005062	EFO:0000574
Ewing sarcoma	1	MONDO:0012817	EFO:0000174

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE1	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02044276	PHASE3	COMPLETED	A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia
NCT01585649	PHASE1	COMPLETED	PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
NCT02306915	PHASE1	COMPLETED	PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants
NCT02527317	Not specified	COMPLETED	Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).